Boston Scientific Seeks To Limit Embolization Device Adverse Event Focus
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific recommends that only serious, device- and procedure-related adverse events be defined during clinical testing of vascular and neurovascular embolization devices